Skip to content

Grab a Peek at Allergan’s Ophthalmology Pipeline

What retinal diseases are most interesting to Allergan? C. David Nicholson, PhD, chief R&D officer, discusses Allergan’s Phase III trials of Abicipar, a promising treatment for AMD that could reduce the number of injections. He also looks earlier in the pipeline, sharing details of a gene therapy drug for retinitis pigmentosa as well as the company’s CRISPR collaboration with Editas Medicine.

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.

Scroll To Top